Federal judge overrules Ohio's Mifeprex law

8 October 2006

A US District judge has ruled that a Ohio state law (HB126) that would restrict the use of Cayman Islands-based drugmaker Danco Laboratories' Mifeprex (mifepristone), the abortifacient commonly referred to as RU-486, is unconstitutional, on the grounds that it is vague and endangers women's health, according to local media reports.

The Ohio legislation would restrict the use of Mifeprex to the Food and Drug Administration's guidelines of doeses of 600mg and only to be used in the first 49 days of gestation. The American College of Obstetricians and Gynecologists argued that the law criminalized and interfered with medical decisions that could be in the best interests of a woman's health.

US Senator Jim DeMint (Republican, South Carolina), is currently blocking the permanent appointment of Andrew von Eschenbach as FDA Commissioner, in protest at the availability of the drug in the USA (Marketletter September 25).

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK



Today's issue

Company Spotlight